New Twice-Yearly Injection Could Revolutionize High Blood Pressure Treatment
- A new clinical trial suggests that a twice-yearly injection could significantly improve the management of hypertension, potentially replacing or supplementing the need for daily blood pressure medications.
- The findings, published in JAMA, focus on an experimental drug called zilebesiran.
- The global study, known as KARDIA-2, involved 663 adults who had high blood pressure that was not well controlled using their standard medications.
A new clinical trial suggests that a twice-yearly injection could significantly improve the management of hypertension, potentially replacing or supplementing the need for daily blood pressure medications.
The findings, published in JAMA, focus on an experimental drug called zilebesiran. The study indicates that a single injection administered every six months may provide sustained reductions in blood pressure over time.
The KARDIA-2 Clinical Trial
The global study, known as KARDIA-2, involved 663 adults who had high blood pressure that was not well controlled using their standard medications.
Participants in the trial received the experimental drug zilebesiran in addition to their existing blood pressure treatments. Researchers observed that patients receiving the injection alongside standard therapy experienced greater reductions in blood pressure compared to those who continued with standard treatment alone.
Dr. Manish Saxena, a hypertension specialist at Barts Health NHS Trust and Clinical Co-Director of the William Harvey Clinical Research Centre at Queen Mary University of London, led the UK portion of the study. He noted that the novelty of this treatment is its long duration.
Hypertension is a global health concern as blood pressure control rates remain poor and is a leading cause of heart attacks and strokes. This study demonstrates the efficacy and safety of zilebesiran, when added to commonly used first line blood pressure lowering drugs. The novelty of this treatment is its long duration; giving just one injection every six months could help millions of patients to better manage their condition.
Dr. Manish Saxena
Mechanism of Action
Zilebesiran utilizes RNA interference technology to lower blood pressure. The drug works by blocking a key protein in the liver, which helps the blood vessels relax.
This approach targets the biological pathways that regulate blood pressure, aiming to provide a long-acting alternative to the daily pill regimens that have been the standard of care for decades.
Addressing the Challenge of Medication Adherence
Hypertension, often referred to as a silent killer
, affects more than one billion people globally. Despite the existence of multiple effective medications, blood pressure control rates remain low due to issues with patient adherence.
Daily pills require consistent administration, long-term motivation, and steady access to prescriptions. Many patients struggle with complex regimens involving multiple drugs or stop taking their medication due to side effects.
The potential for a twice-yearly injection could remove these barriers, reducing the frequency of dosing and minimizing the risk of missed doses.
Public Health Implications
Unmanaged hypertension is a primary risk factor for several serious health complications, including:
- Heart attacks
- Strokes
- Kidney failure
- Dementia
- Premature death
The impact of poor control is particularly evident in specific regions. In India, approximately 31 per cent of adults—roughly one in three—have high blood pressure. However, awareness is reported to be less than 50 per cent, and only about 12 per cent of the approximately 220 million affected individuals have their blood pressure under control.
Similarly, in the UK, high blood pressure affects about 1 in 3 adults, making it a critical driver of cardiovascular disease.
As zilebesiran continues through late-stage global trials, researchers believe this long-acting treatment could dramatically improve long-term blood pressure control for millions of patients worldwide.